Guardant Wins $292 Million in False Advertising Case Against Natera Over Cancer Tests

Guardant Health secured a pivotal victory in its legal battle against Natera, with a federal jury awarding $292.5 million in a false advertising case[1][2]. The lawsuit, which began in May 2021, accused Natera of making misleading comparisons between its Signatera test and Guardant's Reveal liquid biopsy test, designed to detect colorectal cancer[1]. Guardant claimed Natera's advertising falsely emphasized differences in test sensitivities and predictive values to promote a preference for Signatera[2]. The court found these actions to be deceptive, awarding significant compensatory and punitive damages, marking this as one of the largest false advertising verdicts to date[1].